¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple factor hypothesis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù´ë¼º¹ßÀÛ
  • multiple peripheral neuritis
    ´Ù¹ß¸»ÃʽŰ濰
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • multiple pregnancy
    ´ÙÅÂÀÓ½Å, ¹µÀÓ½Å
  • multiple scattering
    ´ÙÁß»ê¶õ
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple sleep latency test
    ¼ö¸éÀẹ±â¹Ýº¹°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple division
    º¹Çպп­
  • multiple dysplasia
    ¹µÇü¼ºÀå¾Ö
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ°ÉÀ½
  • multiple infection
    ¿©·¯¹ø°¨¿°
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ
  • multiple field irradiation
    ´ÙÁ¶»ç¿µ¿ªÁ¶»ç
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Factor VII
    VII ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor VIII
    VIII ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor X activated
    Ȱ¼ºÈ­(üÀàõûù)µÈ X ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor XI
    XI ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Factor XII
    XII ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • Fibrin-stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­)
  • Fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷(àéë«Ù½á¬øà)¼ºÀå¿äÀÎ(à÷íþé©ì×)
  • G-CSF (Granulocyte colony-stimulating factor)
    °ú¸³¼¼Æ÷±ºÃËÁøÀÎÀÚ(Î¨Ø£á¬øàÏØõµòäì×í­)
  • GH releasing factor
    ¼ºÀå(à÷íþ)È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í­).
  • GH releasing factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®ÀÎÀÚ.
  • Growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • Hageman factor
    ÇϰԸ¸ÀÎÀÚ
  • Hydrostatic factor
    Á¤¼öÀÎÀÚ(ð¡â©ì×í­)
  • IGF-I(insulin-like growth factor-I)
    Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ-1
  • Luteinization -inhibiting factor
    Ȳüȭ¾ïÁ¦¿äÀÎ(üÜô÷ûùåäð¤é©ì×)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • familial multiple lipomatosis
    °¡Á·¼º ´Ù¹ß¼º Áö¹æÁ¾Áõ
  • infection, multiple
    ´ÙÁß°¨¿°, º¹¼ö±Õ°¨¿°
  • infectious multiple gangrene of skin
    Àü¿°¼º ÇǺΠ´Ù¹ß¼º ±«Àú
  • least common multiple =LCM
    ÃÖ¼Ò°ø¹è¼ö(ÊÙË­ËÑËà).
  • multiple
    ´Ù¹ß¼ºÀÇ,´Ù¼öÀÇ,´Ù¾çÇÑ
  • multiple
    ´Ù¹ßÀÇ
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(ÒýÛ¡àõÒÛåË).
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(ÒýÛ¡àõÒÛåË)
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(´Ù¹ß¼º³ó¾ç).
  • multiple alleles
    º¹´ë¸³ÀÎÀÚ, ´Ù¹ß¼º ´ë¸³ÇüÁú(ÒýÛ¡àõÓßí¡û¡òõ).
  • multiple allelic mutation
    º¹´ë¸³ÇüÁúº¯ÀÌ(ÜÜÓßí¡û¡òõܨì¶).
  • multiple allelism
    º¹´ë¸³(¼º)(¡­Óßí¡àõ).
  • multiple allelism
    º¹´ë¸³(¼º)(¡­Óßí¡àõ).
  • multiple allelomorph
    º¹´ë¸³À¯ÀüÀÚ(¡­Óßí¡ë¶îîí­).
  • multiple allelomorphism
    º¹´ë¸³¼º(¡­Óßí¡àõ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene hypothesis
    À¯ÀüÀÚ ¼³(ë¶îîí­àã)
  • generation-time hypothesis
    ¼¼´ë ½Ã°£ ¼³(á¦ÓÛãÁÊààã)
  • Haldane-Oparin hypothesis
    Ȧµ¥ÀÎ-¿ÀÆÄ¸°¼³(àã)
  • Jacob and Monod hypothesis
    Àð°ö¡¤¸ð³ë ¼³(àã)
  • justification hypothesis
    "ºÒ°¡ÇǼ³(ÝÕʦù­àã), ¼÷¸í·Ð(âÖÙ¤Öå)"
  • Knoop's hypothesis
    Äí
  • mechanochemical coupling hypothesis
    ±â°èÈ­ÇÐÀû(ѦÌþûùùÊîÜ) ¦Áþ±â¼³(àã)
  • membrane trigger hypothesis
    ¸·À¯¹ß¼³(دë¯Û¡àã)
  • messenger RNA hypothesis
    Àü·É(îîÖµ)RNA¼³(àã)
  • methyl-trap hypothesis
    ¸ÞÆ¿Æ÷ȹ¼³(øÚüòàã)
  • Mitchell hypothesis
    ¹Ìÿ¼³(àã)
  • Murayama hypothesis
    ¹«¶ó¾ß¸¶¼³(àã)
  • Ogston hypothesis
    ¿À±×½ºÅæ¼³(àã)
  • one-enzyme-one-linkage hypothesis
    ÀÏÈ¿¼ÒÀÏ¿¬°ü¼³(ìéý£áÈìé֤μàã)
  • one-gene-one-enzyme hypothesis
    ÀÏÀ¯ÀüÀÚÀÏÈ¿¼Ò¼³(ìéë¶îîí­ìéý£áÈàã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TRH tension-reducing hypothesis; thyrotropin-releasing hormone
DF decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima...
GRF gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow...
HSF heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase...
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MAP Multiple Antigenic Peptide
MCS Multiple Chemical Sensitivities
MCS Multiple Chemical Sensitivity
MCQ multiple choice question
MCA Multiple Classification Analysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple handicapped children
    º¹ÇÕ Àå¾Ö¾Æ
  • multiple infection
    ´Ù¹ß¼º °¨¿°
  • multiple lentigines syndrome
    ´Ù¹ß¼º ÈæÀÚ ÁõÈıº
    »ó¿°»öü¼º ¿ì¼ºÀÇ À¯Àü¼º ÁõÈıºÀ¸·Î¼­ ´Ù¹ß¼º °ËÀº »ç¸¶±Í, ¹«ÁõÈıº¼º ½ÉÀå °áÇÔ. ƯÀÌÇÑ ¾ó±¼ ¸ð¾ç, Æóµ¿¸Æ ÇùÂø, Áö°¢ ½Å°æ¼º ³­Ã», °ñ°Ý ÀÌ»ó, ¾ç¾È °Ý¸®, ¼º±â ±âÇü µîÀ» ³ªÅ¸³½´Ù.
  • multiple myeloma
    ´Ù¹ß¼º °ñ¼öÁ¾, ´Ù¹ß¼º ÇüÁú ¼¼Æ÷Á¾
    1. °ñ¼öÀÇ ¾Ç¼º ½Å»ý¹°. 2. ÇüÁú ¼¼Æ÷ Áúȯ±º Áß °¡Àå Áß¿äÇϰí ÈçÇÑ ÇüÅ·μ­ °ñ°Ý°è¿Í ¶§·Î ¿¬°ñ ºÎÀ§¿¡ ¼º¼÷ ¶Ç´Â ¹Ì¼º¼÷ ÇüÁú ¼¼Æ÷µéÀÌ ´Ù¹ß¼º Á¾±â¸¦ Çü¼ºÇÏ´Â °æ¿ìÀÌ´Ù. 3. ´Ù¹ß¼º °ñ¼öÁ¾Àº ³­Ä¡¼º ¾Ç¼º Ç÷¾× Á¾¾çÀÌ´Ù. ´Ù¸¥ Á¾¾çµé°ú ¸¶Âù°¡Áö·Î ¿øÀÎÀº ¸ð¸£¸ç ÁÖ¿ä Áõ»óÀ¸·Î´Â »ÀÀÇ ¾àÈ­, °ñÀý µîÀÌ °¡Àå ÈçÇϰí, ºóÇ÷, ½Å ºÎÀü, °¨¿° µîÀ¸·Î ³ªÅ¸³­´Ù. º´±â´Â 1, 2, 3±â·Î ³ª´©¸ç ´ë°³ 3±â¿¡ ÁÖ·Î ¹ß°ßµÇ³ª ±Ù·¡¿¡´Â °Ç°­ Áø´Ü µîÀ» ÅëÇØ Á¶±â¿¡ ¹ß°ßµÇ±âµµ ÇÑ´Ù. ´ëÁõÀûÀÎ Ä¡·á°¡ Áß¿äÇϸç Áúȯ ÀÚü¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·áÀÇ ¼ºÀûÀº ¸¸Á·½º·´Áö ¾Ê´Ù. Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº °æ¿ì´Â Æò±Õ ¼ö¸íÀÌ ¼ö°³¿ù¿¡ ºÒ°úÇϰí Ä¡·áÇÑ °æ¿ìÀÇ Æò±Õ ¼ö¸íÀº 3³â Á¤µµÀ̳ª 3±â¿¡¼­´Â 1³â ³»¿ÜÀÌ´Ù. 1990³â´ë¿¡ Ä¡·á ¹æ¹ýÀÌ ¹ß´ÞÇÏ¿© ÀÎÅÍÆä·Ð°ú °ñ¼ö À̽ÄÀÌ ¼Ò°³µÇ¾ú´Ù. ÀÎÅÍÆä·ÐÀº ȯÀÚÀÇ º´ÀÌ ¸¹ÀÌ °¨¼ÒÇÏ¿© Ä¡·á¸¦ Áß´ÜÇÑ °æ¿ì Àç¹ßÀ» ´ÊÃß´Â È¿°ú°¡ °ËÁõµÇ¾ú´Ù. ȯÀÚÀÇ °ñ¼ö, ȤÀº ±ÙÀÚ¿¡´Â ¸»ÃÊÇ÷¾×ÀÇ Á¶Ç÷¸ð¼¼Æ÷¸¦ À̽ÄÇÏ°í °í¿ë·®ÀÇ Ç×¾Ï Ä¡·á¸¦ ÇÏ´Â ÀÚ°¡ ÀÌ½Ä Ä¡·á´Â ÇöÀç±îÁö Æò±Õ ¼ö¸íÀÌ 5³âÀÌ »óÀ¸·Î º¸°íµÇ¾î °ú°ÅÀÇ Ä¡·á¹ý°ú´Â ¿ùµîÇÑ Çâ»óÀ» º¸¿© Ȱ¹ßÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â ÀÚ°¡ À̽Ŀ¡¼­µµ ¾Ï ¼¼Æ÷°¡ ¾ø´Â Á¶Ç÷¸ð¼¼Æ÷¸¸À» ÃßÃâÇÏ¿© À̽ÄÇϴ ÷´ÜÀÇ Ä¡·á¹ýÀÌ ¼Ò°³µÇ°í ÀÖ¾î ¿ÏÄ¡¸¦ ÇâÇØ ÇÑ °ÉÀ½¾¿ ÁøÇàµÇ°í ÀÖ´Ù°í º¸¿©Áø´Ù. ´Ù¹ß¼º °ñ¼öÁ¾ÀÇ Áø´ÜÀº Southwest Oncology Grou
  • multiple myositis
    ´Ù¹ß ±Ù¿°, ´Ù¹ß¼º ±Ù¿°
  • multiple neurofibromatosis
    ´Ù¹ß ½Å°æ ¼¶À¯Á¾Áõ
  • multiple neuroma syndrome
    ´Ù¹ß¼º ½Å°æÁ¾ ÁõÈıº
  • multiple osteoma
    ´Ù¹ß¼º °ñÁ¾
  • multiple papilloma
    ´Ù¹ß¼º À¯µÎÁ¾
  • multiple petechia
    ´Ù¹ß¼º Á¡»ó ÃâÇ÷
  • multiple photoreceptor
    ´Ù¹ß¼º ±¤ ¼ö¿ëü, ´Ù¹ß¼º ±¤ ¼ö¿ë±â
  • multiple projection
    ´Ù¹ß¼º Á¶»ç
  • multiple pulmonary emboli
    ´Ù¹ß¼º Æó »öÀü
  • multiple region
    ´Ù¹ß¼º ºÎÀ§
  • multiple rough gravellike sound
    ´Ù¹ß¼ºÀÇ °ÅÄ£ ÀÚ°¥ °¡´Â ¼Ò¸®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
cancer, multiple myeloma A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
chromosomes in multiple miscarriages Couples who have had more than one miscarriage (spontaneous abortion) have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
miscarriages, multiple, chromosomes in Couples who have had more than one miscarriage have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
multiple Manifold, occurring in or affecting various parts of the body at once.
Origin: L. Multiplex
(18 Nov 1997)
multiple alcohol An alcohol containing more than one OH group.
(05 Mar 2000)
multiple amputation Amputation of two or more limbs or parts of limbs performed at the same operation.
(05 Mar 2000)
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á